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Multidrug resistance is a prevailing phenomenon leading to chemotherapy treatment
failure in cancer patients. In the current study two known cytotoxic pseudoguaianolide
sesquiterpene lactones; neoambrosin (1) and damsin (2) that circumvent MDR were
identified. The two cytotoxic compounds were isolated using column chromatography,
characterized using 1D and 2D NMR, MS, and compared with literature values. The
isolated compounds were investigated for their cytotoxic potential using resazurin
assays and thereafter confirmed with immunoblotting and in silico studies. MDR cells
overexpressing ABC transporters (P-glycoprotein, BCRP, ABCB5) did not confer cross-
resistance toward (1) and (2), indicating that these compounds are not appropriate
substrates for any of the three ABC transporters analyzed. Resistance mechanisms
investigated also included; the loss of the functions of the TP53 and the mutated EGFR.
The HCT116 p53−/− cells were sensitive to 1 but resistant to 2. It was interesting to
note that resistant cells transfected with oncogenic EGFR exhibited hypersensitivity
CS toward (1) and (2) (degrees of resistances were 0.18 and 0.15 for (1) and (2),
respectively). Immunoblotting and in silico analyses revealed that 1 and 2 silenced c-Src
kinase activity. It was hypothesized that inhibition of c-Src kinase activity may explain CS
in EGFR-transfected cells. In conclusion, the significant cytotoxicity of 1 and 2 against
different drug-resistant tumor cell lines indicate that they may be promising candidates
to treat refractory tumors.
Keywords: ABC-transporters, Asteraceae, EGFR, p53, Src inhibition, targeted chemotherapy
INTRODUCTION
Chemotherapy still represents a major treatment option for cancer, despite its limitations
in speciﬁcity and toxicity. Resistance is an everlasting obstacle in cancer therapy eventually
leading to MDR that result to therapy failure. Various factors account for inherent (primary)
and acquired (secondary) resistance including: point mutations in target and eﬀector genes,
Abbreviations: ABC, ATP-binding cassette; CS, collateral sensitivity; DCM, dichloromethane; EGFR, epidermal growth
factor receptor; GBM, glioblastoma multiforme; MDR, multidrug resistance; TP53, tumor suppressor p53.
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genetic, and epigenetic heterogeneity of cancer cells, increased
activity of drug eﬄux pump such as ABC transporters,
activation of EGFR leading to increased proliferation
by auto-activation of downstream signaling cascades,
activation of drug metabolizing enzymes such as CYP450,
impairment of DNA repair mechanisms and suppression of
apoptosis by mutated p53 (Gottesman, 2002; Holohan et al.,
2013).
Resistance to chemotherapy remains a key challenge;
therefore, targeted chemotherapy emerged as new concept in
the treatment regime. In this treatment, a drug speciﬁcally
inhibit tumor growth by targeting cellular molecules that are
pivotal for growth, progression, and metastasis, for example
using monoclonal antibodies or natural or synthetic small
molecule inhibitors. This approach increased the speciﬁcity
of treatment for diﬀerent types of malignancies, including
breast, colorectal, lung, and pancreatic cancers, as well
as lymphoma, leukemia, and multiple myeloma (Gerber,
2008).
Natural products considerably impact drug discovery due
to their wide structural diversity. More than 60% of clinically
used anticancer agents are derived from natural sources (plants,
marine organisms, and microorganisms; Newman and Cragg,
2012).
Ambrosia maritima L. (Asteraceae) is gray-hairy herb, richly
branched with ﬁnely dissected, fragrant leaves. This plant is
widely distributed in the central and northern Sudan, near
the banks of Nile River and locally known as Damsisa.
It is used in folk medicine to treat diabetes, hypertension,
urinary tract infections, gastrointestinal disturbances, kidney
stones, and also cancer (Khalid et al., 2012; Dirar et al.,
2014). A. maritima has been planted in Egypt, on canals
and banks of the Nile Delta as a molluscocide against
the schistosomiasis intermediate host (El-Sawy et al., 1981).
Recently, it has been reported that A. maritima exhibited
considerable cytotoxic activity against various MDR tumor
cells (Saeed et al., 2015). Several genera of Asteraceae are
rich of sesquiterpene lactones (SLs), which are considered
as promising class of compounds because of their diverse
biological activity with interesting therapeutic mechanisms,
including anti-inﬂammatory, antitumor, antimicrobial, and
antiviral properties (Zhang et al., 2005; Fraga, 2011; Merfort,
2011).
In the present work, two pseudoguaianolide SLs, neoambrosin
(1) and damsin (2), were characterized from A. maritima
L. Their anticancer activities against drug-resistant tumor
cell lines were determined, in which either MDR-conferring
ABC-transporters [P-glycoprotein (P-gp), BCRP, ABCB5] or
mutation-activated EGFR were overexpressed. Furthermore,
drug-resistant TP53-knockout cells were analyzed. The focus
of this study was on EGFR-downstream signals due to
the striking hypersensitivity CS of EGFR-transfected cells
toward 1 and 2. The two compounds which are structurally
related, speciﬁcally inhibited c-Src kinase activity, indicating
that this oncogenic kinase is a suitable target of 1 and 2,




Pure DCMwas used to prepare crude extract from whole plant of
A. maritima. Crude extract was analyzed by high pressure liquid
chromatography (HPLC, Agilent 1100 Series, equipped with a
LiChrospher RP 18 column (3 mm × 125 mm; 5 μm, Merck,
Darmstadt, Germany) at 40◦C and a ﬂow rate of 1 mL/min
with an elution gradient composed of H2O + 0.1% (v/v)
triﬂuoroacetic acid and acetonitrile. The molecular weight of the
selected peaks was determined by HPLC-MS (Agilent 1260 Series
LC and 6130 Series Quadrupole MS System). The mass spectra
were recorded using atmospheric pressure chemical ionization
(APCI) with positive and negative polarization. A Superspher
RP 18 (125 mm × 2 mm; 4 μm, Merck) column was used at
40◦C. For every run, 1 μL of a sample (1 mg/mL) was injected.
Chromabond column (C18 ec-column, Macherey–Nagel, Düren,
Germany) was used to obtain the pure compounds. 1D and 2D
NMR data were recorded with a Bruker AVANCE III-600 MHz
spectrometer equipped with a 5 mm inverse TCI cryoprobe
using standard pulse sequences to elucidate the structures of
neoambrosin (1) and damsin (2).
Plant Material
The whole plant of A. maritima was identiﬁed and authenticated
by Prof. Hassan Khalid at medicinal and aromatic plants research
institute (MAPRI) in Khartoum. A voucher specimen (A23)
represents the plant was deposited in the herbarium of National
Research Institute, Khartoum, Sudan (Saeed et al., 2015).
Extraction and Isolation of Neoambrosin
(1) and Damsin (2) from the Whole Plant
of A. maritima
Plant materials (∼100 g) was dried and ground before being
subjected to cold maceration with DCM. The plant powder was
macerated with overnight gentle shaking in DCM into stoppered
ﬂask at room temperature. The extracted solvent was separated
and ﬁltered through Whatman no. 1 ﬁlter paper. The DCM was
evaporated under reduced pressure using rotatory evaporator,
resulting in A. maritima crude extract.
One gram of the whole plant of A. maritima extract was
subjected to separation using a silica gel-60 matrix eluting
with cyclohexane (C6H10): Ethyl acetate (EtOAc) gradient
in increasing polarities. This resulted into 10 fractions each
including: 1 (2 mg), 2 (103 mg), 3 (66 mg), 4 (107 mg), 5 (67 mg),
6 (71 mg), 7 (37 mg), 8 (45 mg), 9 (37 mg), 10 (415 mg). The
10 samples were fractionated via HPLC in micro-titer plates in
order to determine their cytotoxic potential. The samples were
fractionated using the analytical HPLC method given above. A
subsequent located fraction collector (Agilent 1100 Series) was
used equipped with 96-well plates for collecting the ﬂow through
resulting in 92 diﬀerent fractions of 250 μl each. These fractions
could be used in biological assays. Fractions 3 and 4 of the
main column revealed interesting cytotoxic activities (IC50 values
of 4.5 and 4.8 μM for fractions 3 and 4) against CCRF-CEM
cells, respectively. These fractions were subsequently subjected
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to solid phase extraction using C18- Chromabond column as
the stationary phase eluting with neat methanol (MeOH). The
resultant fractions were further puriﬁed by preparative HPLC
using 65% acetonitrile with 35% H2O + 0.1% (v/v) triﬂuoracetic
acid for fraction 3, and 60% acetonitrile with 40% H2O + 0.1%
(v/v) triﬂuoracetic acid, with 17 mL/min isocratic ﬂow-rate,
yielding compounds 1 (20.0 mg) and 2 (50.5 mg), respectively.
Cell Lines
Drug sensitive CCRF-CEM and multidrug-resistant P-gp-
overexpressing CEM/ADR5000 leukemic cells were cultured
in RPMI-1640 medium supplemented with 10% FBS
and 1% penicillin/streptomycin (Invitrogen, Darmstadt,
Germany). Doxorubicin (5000 ng/mL) was added to maintain
overexpression of P-gp (MDR1, ABCB1) in resistant cells
(Kimmig et al., 1990). Breast cancer cells transfected with a
control vector (MDA-MB-231-pcDNA3) or with cDNA for the
breast cancer resistance protein BCRP/ABCG2 (MDA-MB-
231-BCRP clone 23) were cultured and maintained as reported
(Doyle et al., 1998). Expression of ABCG2 in resistant cells
was maintained by geneticin (800 ng/mL) (Eﬀerth et al., 2003).
Human HEK293-ABCB5 embryonic kidney cells transfected
with another ABC-transporter, ABCB5, were propagated
in DMEM medium supplemented with 10% FBS and 1%
penicillin/streptomycin (Invitrogen) (Kawanobe et al., 2012).
Non-transfected HEK293 cells served as control. Human wild-
type HCT116 colon cancer cells (p53+/+) and knockout clones
(p53−/−) derived by homologous recombination (Waldman
et al., 1995; Bunz et al., 1998) were generously provided by Dr.
B. Vogelstein and H. Hermeking (Howard Hughes Medical
Institute, Baltimore, MD, USA). Both colon cancer cells were
cultured in DMEM medium supplemented with 10% FBS and
1% penicillin/streptomycin (Invitrogen). Wild-type human
GBM U87MG cells and cells transfected with control mock
vector or an expression vector harboring EGFR cDNA with a
deletion in exons 2–7 (U87MGEGFR), were kindly provided
by Dr. W. K. Cavenee (Ludwig Institute for Cancer Research,
San Diego, CA, USA; Huang et al., 1997). Six non-transfected
human GBM cell lines were used, which overexpress c-Src
including: A172, T98G, and U251MG cells, obtained from the
German Cancer Research Center (DKFZ, Heidelberg, Germany).
DK-MG and SNB-19 cells were kindly provided by Dr. Tcholpon
Djuzenova (Department of Radiation Oncology, University
Hospital, Würzburg, Germany). BS153 cells were obtained from
Dr. Alexander Schulte (Department of Neurosurgery, University
Medical Center Hamburg-Eppendorf, Hamburg, Germany) and
originally generated by Dr. Adrian Merlo (Jones et al., 2001).
All GBM cells were cultured in DMEM medium supplemented
with 10% FBS and 1% penicillin/streptomycin (Invitrogen). All
cell lines were incubated in a humidiﬁed 5% CO2 atmosphere at
37◦C and passaged twice weekly.
Cytotoxicity Assays
The resazurin (Promega, Mannheim, Germany) reduction assay
was performed to assess cytotoxicity of neoambrosin (1) and
damsin (2) in a concentration range of 0.001–1000 μM as
previously described (Kuete and Eﬀerth, 2013). The IC50 values
have been calculated from dose response curves and resistance
ratios were determined by dividing the IC50 of resistant cells by
the IC50 of the corresponding parental cells. Each assay has been
done thrice with six replicates for each concentration.
Epidermal Growth Factor Receptor
Signaling Proteins Analyses by
SDS-PAGE and Immunoblotting
Tumor cells (500,000 cells/well) were treated with neoambrosin
(1) and damsin (2), harvested after 24 h, and washed with
PBS. Total proteins were extracted by the Mammalian Protein
Extraction Reagent (M-PER) (Thermo Scientiﬁc, Rockford, IL,
USA) containing protease inhibitor and phosphatase inhibitor
(Roche, Mannheim, Germany). Cells were shaken at 4◦C for
30 min, cell lysates were centrifuged at 14,000 × g for
15 min and supernatants were transferred to new tubes. Protein
concentrations in lysates were detected by NanoDrop1000
(PEQLAB, Erlangen, Germany). Thirty micrograms of protein
were electrophoresed on 10% SDS-polyacrylamide gels and
blotted onto polyvinylidene diﬂuoride (Ruti R©-PVDF) membrane
(Millipore Corporation, Billerica, MA, USA) using wet sandwich
blotting. Membranes were washed using Tris-buﬀered saline
containing 0.5% Tween-20 (TBST), then blocked with 5%
(w/v) bovine serum albumin in TBST for 1 h at room
temperature. Membranes were incubated at 4◦C overnight
with primary antibodies (Cell Signaling Technology, Frankfurt,
Germany) including: phosphorylated EGFR (Tyr1068) (1:1000),
phosphorylated STAT5 (Tyr694) (1:1000), phosphorylated Akt
(Ser473) (1:1000), phosphorylated MAPK (Thr202/Tyr204)
(1:1000), phosphorylated Src (Tyr416) (1:1000), Src (1:1000),
and β-actin (1:2000). After washing membranes three times
with TBST, the blots were probed with horseradish peroxidase-
linked anti-rabbit IgG secondary antibodies (1:2000) for 2 h at
room temperature. Finally, LuminataTM Classico Western HRP
substrate (Merck Millipore, Schwalbach, Germany) was added
for 5 min in the dark. Alpha Innotech FluorChem Q system
(Biozym, Oldendorf, Germany) was used for documentation and
band analysis (Zhao et al., 2015).
Molecular Docking
Molecular docking predicts in silico the interaction, aﬃnity,
and geometry of ligands with target proteins. The aﬃnity
of neoambrosin (1) and damsin (2) to c-Src kinase domain
compared with the known c-Src inhibitor dasatinib (3) (Buettner
et al., 2008; Ceppi et al., 2009) was studied using Autodock4,
Lamarckian algorithm (Morris et al., 2009). The compounds were
prepared as 3D-structures and converted to PDBQT format. The
c-Src kinase domain was obtained from the Protein Data Bank
(PDB ID: 3QLG). Non-standard residues of protein (HETATM)
were excluded, hydrogens added, non-polar hydrogen atoms
merged, missing atoms supplemented and attached to solvation
parameters. Afterward, a grid box was assigned to cover the
c-Src kinase domain (PDBQT format). Docking parameters
were set to 250 runs and 2,500,000 energy evaluations for each
cycle. Docking was performed three times independently to
calculate mean values and standard deviations of lowest binding
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energies and predicted inhibition constants (Pki), which were
obtained from the docking log ﬁles (dlg). Binding poses between
ligands (neoambrosin (1), damsin (2) and dasatinib (3)) and the
macromolecule (c-Src kinase domain) were visualized by Visual
Molecular Dynamics software (University of Illinois, Champaign,
IL, USA).
RESULTS
Identification and Structure Elucidation
of Neoambrosin (1) and Damsin (2)
Two compounds 1 and 2 were identiﬁed from pure DCM
extract of the whole plant of A. maritima L. (Figure 1).
Neoambrosin (1) was obtained as colorless oil. Its structure
was established by NMR. The 13C NMR spectrum revealed 15
signals. According to HSQC, they originated from CH3 groups
(δ 1.14/15.2, δ 1.18/21.5), CH2 groups including one oleﬁnic
[δ (1.77, 1.82)/31.4, δ (2.06, 2.15)/24.7, δ (2.74, 3.22)/40.7, (δ 5.64,
6.19)/120.5], CH groups including one oleﬁnic (δ 2.93/40.2,
δ 3.49/44.8, δ 4.55/81.6, δ 6.03/125.7), and quaternary carbons
(δ 59.9, 140.8, 150.4, 172.2, 216.2). These spectra data were
suggestive of SLs. The skeleton and the relative conﬁguration of
the pseudoguaianolide (1) was conﬁrmed from 2D NMR analysis
(including COSY, HMBC, and NOESY) and comparison with
literature values from previous studies. The 1D and 2D spectral
data of this compound completely matched those of neombrosin
(1), previously isolated from the aerial parts of A. maritima
(Salam et al., 1984) and the vegetative parts of a related species,
A. hispida by Herz et al. (1981).
Damsin (2) was isolated as colorless oil. Its 13C NMR
spectra also contained 15 signals. The lack of two oleﬁnic
resonances suggested 2 as a reduced form of 1. Based on HSQC
correlations, two CH3 groups (δ 1.08/14.0, δ 1.08/16.0), ﬁve CH2
groups including one oleﬁnic exo-methylene (δ 1.75,1.80/33.6,
δ 1.80, 2.01/24.1, δ 1.80, 2.01/25.9, δ 2.24, 2.48/36.2, δ5.54,
6.28/121.1), four CH groups (δ 2.20/34.5, δ 2.01/46.3, δ 3.30/44.6,
δ 4.53/81.9) and four quaternary carbons (δ 55.1, 139.7,
170.3, 219.1) were identiﬁed. The HMBC correlations indicated
another pseudoguaianolide. The relative stereochemistry and the
structure matched that of damsin, as previously reported by Herz
et al. (1981).
Cytotoxicity of Neoambrosin (1) and
Damsin (2)
Neoambrosin (1) and damsin (2) were tested in a range from
10−3 to 103 μM in resazurin assays. Firstly, the eﬀects of 1 and
2 on drug sensitive CCRF-CEM and resistant CEM/ADR5000
cells were analyzed. No cross-resistance was observed (Figure 2A;
Table 1). The IC50 values were similar in both cell lines (degrees
of resistance were 1.07 and 1 for 1 and 2, respectively). Similarly,
BCRP-transfected MDA-MB-231 cells were not cross-resistant
to these compounds (Figure 2B; Table 1). Multidrug-resistant
ABCB5-transfectants did also not show resistance toward these
SLs (Figure 2C; Table 1).
Then, neoambrosin (1) and damsin (2) were tested on wild-
type HCT116 p53+/+ and HCT116 p53−/− knockout cells
(Figure 2D; Table 1). Both cell lines showed sensitivity to
neoambrosin (1) (degree of resistance was 1.5), whereas knockout
cells exhibited 4.1-fold cross-resistance to damsin (2) compared
to wild-type cells.
Surprisingly, U87.MGEGFR cells were hypersensitive
toward both compounds as compared to U87MG wild-type cells.
The degrees of resistances were 0.18 and 0.15 for neoambrosin
FIGURE 1 | Chemical structures of neoambrosin (1) and damsin (2) and HPLC profiling of Ambrosia maritima L. dichloromethane (DCM) extract.
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FIGURE 2 | Dose response curves of neoambrosin (1) and damsin (2) as determined by resazurin assays. (A) Cytotoxicity against drug-sensitive parental
CCRF-CEM tumor cells and their P-glycoprotein (P-gp; MDR1/ABCB1)-expressing, multidrug-resistant subline, CEM/ADR5000. (B) Cytotoxicity against
MDA-MB-231-pc DNA cells and their BCRP-transduced subline, MDA-MB-231-BCRP. (C) Cytotoxicity against HEK293 cells and their ABCB5-transfectant subline,
HEK293/ABCB5. (D) Cytotoxicity against HCT116 cells (p53+/+ ) and their knockout subline (p53− /−). (E) Cytotoxicity against U87MG cells and their EGFR-
transduced subline, U87MGEGFR. The dose response curves show mean values ± SD of three independent experiments with each six parallel measurements.
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TABLE 1 | IC50 values of different drug-sensitive and -resistant cell lines of
neoambrosin (1) and damsin (2).
Compound Cell lines Resistance
ratio (RR)
CCRF-CEM CEM/ADR5000
Neoambrosin 4.5 ± 0.2 μM 4.8 ± 0.2 μM 1.07





Neoambrosin 29.9 ± 1.7 μM 43.3 ± 4.9 μM 1.4
Damsin 33.8 ± 8.4 μM 46.4 ± 2.6 μM 1.4
HEK293 HEK293/ABCB5
Neoambrosin 4.5 ± 0.6 μM 4.8 ± 0.2 μM 1.07
Damsin 4.5 ± 0.1 μM 4.6 ± 0.6 μM 1
HCT116 P53+/+ HCT116 P53−/−
Neoambrosin 26.5 ± 6.9 μM 39.4 ± 6.4 μM 1.5
Damsin 32.5 ± 6 μM 133.6 ± 18.4 μM 4.1
U87MG U87EGFR
Neoambrosin 132.2 ± 2.4 μM 24.1 ± 1.4 μM 0.18
Damsin 154.4 ± 8.9 μM 24.1 ± 1.5 μM 0.15
(1) and damsin (2), respectively (Figure 2E; Table 1). This
phenomenon is known as collateral sensitivity (CS) (Hall et al.,
2009) and suggests that both SLs may target proteins involved in
EGFR signaling.
Inhibition of EGFR Signaling Cascades
by Neoambrosin (1) and Damsin (2)
In order to have a closer insight into the phenomenon of CS of
U87.MG cells transfected with deletion-activated EGFR toward
neoambrosin (1) and damsin (2), the phosphorylation status
of EGFR signaling proteins as parameter of their activation
during signal transduction was investigated. Two concentrations
of each compound were selected: 25 μM (∼IC50) and 100 μM
(4 × IC50). Both compounds inhibited STAT5 and AKT
phosphorylation at 100 μM, whereas other signaling proteins
were not aﬀected, including EGFR (Figure 3A). It was surmised
that STAT5 and AKT activation works independently from EGFR
activation (Okutani et al., 2001; Haynes et al., 2003; Summy
and Gallick, 2006). Then the two compounds 1 and 2 were
hypothesized to target c-Src. Remarkably, they inhibited c-Src
autophosphorylation at Tyr416, whereas non-phosphorylated
(total) c-Src was not aﬀected. These results indicated that both
compounds targeted c-Src and silenced its downstream signaling.
For conﬁrmation, six other glioblastoma cell lines with known
c-Src overexpression were investigated. Indeed, neoambrosin
(1) and damsin (2) inhibited c-Src phosphorylation in all
concentrations tested (Figure 3B).
In silico Binding of Neoambrosin and
Damsin to c-Src
In silico molecular docking of the c-Src kinase domain to both
SLs and dasatinib (3) as positive control, were performed. The
binding energy of dasatinib (3) to c-Src was slightly lower than
those of neoambrosin (1) and damsin (2) (Table 2). Interestingly,
all three compounds bound to the same site on the c-Src kinase
domain. The c-Src kinase domain consists of characteristic small
amino-terminal and large carboxyl-terminal lobes. The catalytic
ATP binding site lies in a cleft between the two lobes. These
lobes move relative to each other and open or close the cleft. The
open form is necessary to allow access of ATP to phosphorylate
c-Src. The residues, which are essential for c-Src phosphorylation
are Lys295 and Asp404. Any molecule able to interrupt the
open/closed c-Src form is considered to have an inhibitory eﬀect
(Hanks et al., 1988; Roskoski, 2004). Importantly, neoambrosin
(1), damsin (2), and dasatinib (3) have the ability to bind to
the cleft between the lobes. Although dasatinib revealed better
aﬃnity, both SLs bind nevertheless to the same binding site
as dasatinib (3) (Table 2; Figure 4). This result explains the
inhibition of c-Src phosphorylation by neoambrosin (1) and
damsin (2).
DISCUSSION
Sesquiterpene lactones gathered attention for cancer treatment
(Lopez-Anton et al., 2007; Staudt, 2010). The cytotoxicity of
pseudoguaianolide SLs, neoambrosin (1) and damsin (2) from
A. maritima L. was tested. Neoambrosin (1) and damsin (2)
inhibited all cell lines tested in the micromolar ranges. While the
cytotoxicity of damsin (2) against cancer cells has been reported
elsewhere (Villagomez et al., 2013), neoambrosin’s cytotoxic
activity is reported here for the ﬁrst time to the best of our
knowledge.
ABC-transporter-mediated MDR leads to reduced
chemotherapeutic drugs accumulation inside the cells, including
anthracyclines, Vinca alkaloids, colchicine, epipodophyllotoxins,
taxanes, camptothecins, imatinib, methotrexate, and
mitoxantrone (Raaijmakers et al., 2006; Eﬀerth et al., 2008;
Fletcher et al., 2010). Among the 48 members of the ABC
transporter family, P-gp and BCRP have been extensively
characterized (Gros et al., 1986; Ueda et al., 1986; Doyle et al.,
1998). Frank et al. cloned a novel ABC transporter named
ABCB5, which controls progenitor cell fusion by altering the
membrane potential in normal melanocytes expressing the
stem cell marker CD133 (Frank et al., 2003). ABCB5 is closely
related to P-gp and confers doxorubicin resistance in malignant
melanoma (Frank et al., 2005). Furthermore, it mediates
resistance to paclitaxel and docetaxel (Kawanobe et al., 2012).
Cell models, which overexpressed these three ABC transporters
were used. Importantly, they did not confer cross-resistance to
neoambrosin (1) and damsin (2), indicating that they are not
substrates for any of these three transporters. This implies that
these SLs may be useful to treat MDR- tumors.
One of the most frequently mutated genes is the TP53. It
is impaired in approximately 50% of all tumors (Nigro et al.,
1989; Olivier et al., 2002). As transcription factor, p53 maintains
the genomic integrity after genotoxic stress by inducing cell
cycle arrest, DNA repair, and apoptosis (Vogelstein et al., 2000).
Activated p53 spurs p21/WAF1, an inhibitor for G2/M-speciﬁc
cell division control protein 2 kinase and cyclin-dependent G1
kinase subsequently leading to G2/M and G1 checkpoint control.
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FIGURE 3 | Western blot analysis of the effect of neoambrosin (1) and damsin (2) on EGFR and its downstream signaling cascade proteins. (A) Effect
on phosphorylation of EGFR, STAT5, Akt, MAPK (Erk1/2), c-Src, and total c-Src. Bands were normalized to β-actin in order to obtain numerical values
(Mean ± SEM). Bars of the average and error bars of three independent experiments are shown. Statistical analysis was done by paired student’s t-test
∗∗p < 0.01,∗p < 0.05; paired t-test. (B) Effect on phosphorylation of c-Src in different GBM cell lines that highly overexpressed c-Src (A172, DK-MG, SNB-19,
U251.MG, BS153, and T98G). β-actin was used as loading control.
Failure in arresting cells at both checkpoints due to mutated
p53 confers drug resistance (Agarwal et al., 1995; Piovesan et al.,
1998). HCT116 p53−/− cells, which have been reported for their
resistance to 5-FU, irinotecan, and oxaliplatin (Boyer et al., 2004)
were tested. Interestingly, wild-type and knockout HCT116 cells
were sensitive to neoambrosin (1), while knockout cells were
cross-resistant to damsin (2). This indicates that both SLs may
TABLE 2 | Molecular docking of dasatinib (3), neoambrosin (1), and damsin
(2) to the c-Src kinase domain.
Compound Lowest binding
energy (kcal/mol)
Pki (µM) AA involved in
H-bonds
Dasatinib –9.85 ± 0.03 0.06 ± <0.00 Thr338, Met341
Neoambrosin –7.23 ± <0.00 4.99 ± <0.00 Asp404
Damsin –7.25 ± 0.01 4.8 ± 0.01 Asp404
Shown are lowest binding energy, predicted inhibition constant (Pki), and amino
acids (AA) involved in hydrogen bonding. Each docking experiment has been
repeated three times.
activate wild-type p53 triggering their programmed death. This
result is in agreement with a previous study on another SL,
parthenolide, which activated p53 by enhancing ubiquitylation
and degradation of the p53-negative regulator Mdm2 (Gopal
et al., 2009). The sensitivity of p53-knockout cells to neoambrosin
(1) could be due to targeting other molecular determinants,
whereas damsin (2) failed to address these targets. This result
warrants more detailed investigation in the future.
Epidermal growth factor receptor and its downstream
signaling proteins are associated with MDR and up-regulated
co-expression of ABC-transporters (Hirsch-Ernst et al., 1995;
Garcia et al., 2006; Katayama et al., 2007; Hoﬀmann et al., 2011).
Oncogenic EFGR confers resistance by inducing expression
of the anti-apoptotic protein Bcl-xL (Nagane et al., 1998).
Several EGFRmutations have been described. A commonmutant
is EFGR, which causes poor prognosis and survival times,
especially in glioblastoma patients (Shinojima et al., 2003). An
801 bp in-frame deletion of the extracellular EGFR domain
results in ligand-independent receptor activation, consequent
auto-phosphorylation of tyrosine residues in the kinase domain
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FIGURE 4 | Molecular docking of dasatinib (3), neoambrosin (1), and damsin (2) to the c-Src kinase domain. The protein was represented by its secondary
structure in a new carton format, whereas ligands were represented in dynamic bond format with different colors: dasatinib (3) (red), neoambrosin (1) (green) and
damsin (2) (blue). Amino acids (AA) involved in H-bonds were shown in a bold font Met341 and Thr338 (dasatinib); Asp404 (neoambrosin and damsin).
and induction of downstream signaling (Nishikawa et al., 1994).
Surprisingly, neoambrosin (1) and damsin (2) revealed CS in
U87MGEGFR cells compared to U87MG wild-type cells. CS
represents a strategy to preferentially kill resistant cells (Hall
et al., 2009). CS is well known from MDR phenotypes with
P-gp overexpression. Several hypotheses attempted to explain CS,
e.g. increased production of reactive oxygen species (ROS) in
expense of ATP hydrolysis, expelling endogenous vital substrates,
exploitation of energetic sensitivities and plasma membrane
disruption (Pluchino et al., 2012). CS in EGFR-expressing cells
has been recently described for the ﬁrst time by us (Saeed
et al., 2014). SLs induce oxidative stress and disturb the redox
status by increased ROS production through interaction with the
sulfhydryl moiety in the cysteine of the antioxidant glutathione
(Sun et al., 2010). This is in accordance with the assumption
that CS occurs because of ROS accumulation. However, this
explanation may be insuﬃcient, because in this case all other
resistant cell lines tested by us should also exert CS because of
glutathione abundance in all these cell lines.
To further explore CS, we performed phosphorylation-speciﬁc
immunoblotting analyses of EGFR and its downstream signal
transducers. Interestingly, only AKT and STAT5 phosphorylation
was downregulated, whereas EGFR and MAPK remained
unaﬀected by the two compounds. This result raises the question
about other targets of these SLs. Another key player of EGFR
signaling is the oncogenic tyrosine kinase, c-Src. Worth to
mention, inhibition of c-Src kinase activity diminished tyrosine
phosphorylation of STAT5 in K562 cells, indicating that Src
activates STAT5 (Okutani et al., 2001; Silva, 2004; Figure 5).
Furthermore, c-Src activated AKT through the formation of a
complex with regulatory subunit p85 of PI3K with subsequent
activation of the PI3K/Akt pathway (Haynes et al., 2003; Summy
and Gallick, 2006; Figure 5). Thus, c-Src inhibition could silence
STAT5 and AKT phosphorylation.
Src was discovered in Rous sarcoma virus that causes
transmissible tumors in chicken (Rous, 1911; Martin, 1970;
Courtneidge, 2002). The viral gene product, v-Src, is a tyrosine
kinase with a cellular homolog, c-Src (Czernilofsky et al.,
1980). Upon c-Src activation, it becomes an oncogene involved
in adhesion, growth, angiogenesis, and progression (Irby and
Yeatman, 2000). Several studies reported elevated expression
and kinase activity of c-Src in many tumor cells as compared
with normal cells, suggesting that c-Src is crucial for cancer
development and progression (Cartwright et al., 1989; Budde
et al., 1994; Muthuswamy et al., 1994; Irby and Yeatman,
2000). c-Src has a great metastatic potential (Yeatman, 2004).
The activity of c-Src tyrosine kinase interacts with receptor of
tyrosine kinases such as EGFR in promoting tumor growth.
The combination of EGFR and c-Src expressions in ﬁbroblasts
leads to synergistic tumorigenicity, if compared with EGFR or
c-Src alone (Maa et al., 1995; Mao et al., 1997; Tice et al.,
1999; Irby and Yeatman, 2000). c-Src activation increased growth
rates and invasion characteristics of tumors. It also decreased
apoptosis in tumor cells (Irby and Yeatman, 2000). Therefore, it
is generally assumed that inhibition of c-Src function represents
an attractive target to stop tumor growth. The recent use of
c-Src inhibitors or antisense therapy in nude mouse studies,
pancreatic cell growth, and leukemia cells supports the validity
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FIGURE 5 | c-Src downstream signaling pathways. In tumor cells, overexpression of c-Src leads to constitutive activation of PI3K/Akt and STATs (STAT3 and
STAT5) pathways. This activation governing cancer development and progression. PI3K, phosphatidylinositol-3-kinase; IKK, IκB kinase; NFκB, nuclear factor
kappa-light-chain-enhancer of activated B cells; STAT, signal transducers and activators of transcription.
of this concept (Staley et al., 1997; Lutz et al., 1998; Roginskaya
et al., 1999).
It has been postulated that c-Src could be a target for
neoambrosin (1) and damsin (2) and that CS emerged in
EGFR-expressing cells due to c-Src inhibition. We further
investigated, how c-Src expression is aﬀected in diﬀerent other
brain tumor models with c-Src overexpression upon treatment
with these two SLs. Interestingly, both compounds inhibited c-Src
phosphorylation not only in EGFR-transfected cells, but also
in six other c-Src-overexpressing cell lines. Further conﬁrmation
came from in silicomolecular docking studies. Neoambrosin (1),
damsin (2), and dasatinib (3) bound to the cleft between the
two c-Src’s lobes. These small amino-terminal and large carboxyl
lobes are of crucial importance for ATP binding to activate c-Src,
thus, blocking of this cleft leads to impaired c-Src activation.
These results indicate that neoambrosin (1) and damsin (2)
are interesting c-Src inhibitors. Recent studies have shown that
targeted inhibition of c-Src by dasatinib leads to decreased
growth, and induced cell-cycle arrest and apoptosis in a subset of
thyroid cancer and breast cancer cells. This therapeutic approach
has been veriﬁed in vitro by immunoblotting analysis (Nautiyal
et al., 2009; Chan et al., 2012). In this respect, it is remarkable that
neoambrosin (1) and damsin (2) reveal similar c-Src-inhibiting
features as dasatinib. Hence, it is reasonable to conclude that
the inhibition of c-Src function (i.e., phosphorylation) led to the
inhibition of tumor cell growth, which we observed in resazurin
assays.
A previous study demonstrated that damsin (2) inhibited
STAT3 and NF-κB expression in Jurkat and Hela cells by
interfering with their signaling pathways (Villagomez et al.,
2013). This result is in accordance with our ﬁnding that damsin
(2) inhibited a master regulator upstream of STAT3 and NF-
κB. Interestingly, c-Src directly activates STAT3, and NF-κB is
activated by the PI3K/Akt pathway (Silva, 2004; Summy and
Gallick, 2006). AKT enhances the transcriptional activity of NF-
κB by phosphorylation and subsequent degradation of inhibitor
of κB (IκB) (Bai et al., 2009). Moreover, several studies stated that
PI3K/Akt pathway regulates the expression of P-gp (ABCB1) and
BCRP (ABCG2) (Figure 5) (Barancík et al., 2006; Chiarini et al.,
2008; Pick andWiese, 2012).
Noteworthy, there is a cross talk between c-Src and p53.
c-Src suppressed the apoptotic p53 pathway (Courtneidge, 2002;
Polonio-Vallon et al., 2014). This may explain the sensitivity of
wild-type 53 cells to neoambrosin (1) and damsin (2) and that
they probably exert their cytotoxicity toward wild-type 53 cells
by c-Src inhibition.
CONCLUSION
Neoambrosin (1) and damsin (2) isolated from the whole
plant of A. maritima L. possess remarkable cytotoxicity against
diﬀerent drug-resistant tumor cell lines. Both SLs silenced c-Src
phosphorylation, which represents an interesting approach for
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targeted therapy, because c-Src is activated in many human
cancers (Yeatman, 2004). The remarkable CS of neoambrosin
(1) and damsin (2) toward EGFR-expressing cells opened
prospects for synergistic tumor killing if combined with
established anticancer drugs. Clinically, tumors develop
MDR and activate alternative pathways to survive and
disseminate. Thus, combination therapies with these two
SLs might improve cure rates of cancer patients (Shapiro,
1955; Devita et al., 1970; Rougier and Lepère, 2005; Li et al.,
2014).
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